A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review
Introductionmost sympathetic paragangliomas are driven by germline pathogenic variants. Identifying germline succinate dehydrogenase B (SDHB) pathogenic variant has important management implications. Here we report a novel germline variant in the SDHB gene in a patient with metastatic paraganglioma...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1577421/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389215575441408 |
|---|---|
| author | Stella Bernardi Stella Bernardi Stefania Zovato Gianmaria Pennelli Marco Cavallaro Matteo Rovina Chiara Dobrinja Chiara Dobrinja Alessandra Guglielmi Fabrizio Zanconati Fabrizio Zanconati Daniela Mazzà Alberto Nieri Mirco Bartolomei Francesca Schiavi |
| author_facet | Stella Bernardi Stella Bernardi Stefania Zovato Gianmaria Pennelli Marco Cavallaro Matteo Rovina Chiara Dobrinja Chiara Dobrinja Alessandra Guglielmi Fabrizio Zanconati Fabrizio Zanconati Daniela Mazzà Alberto Nieri Mirco Bartolomei Francesca Schiavi |
| author_sort | Stella Bernardi |
| collection | DOAJ |
| description | Introductionmost sympathetic paragangliomas are driven by germline pathogenic variants. Identifying germline succinate dehydrogenase B (SDHB) pathogenic variant has important management implications. Here we report a novel germline variant in the SDHB gene in a patient with metastatic paraganglioma and his response to available treatments.Case presentationa 37-year-old Serbian man was admitted to hospital due to hypertension, tachycardia and hyperhidrosis. Screening for secondary hypertension revealed elevated 24-h urinary normetanephrine. A CT scan showed the presence of a 54 x 76 mm retroperitoneal mass that surrounded the aorta, which was located below the pancreas and behind the duodenum. The patient was diagnosed having extra-adrenal sympathetic metastatic paraganglioma (PGL), for which we scheduled debulking surgery and genetic testing. Tumor debulking improved patient symptoms as well as signs of catecholamine excess and tumor mass effects. Meanwhile waiting for next-generation sequencing (NGS) results, the patient started a treatment with sunitinib. At this point, NGS results showed a novel and previously not reported germline SDHB c.314T>A gene variant, which was initially classified as a class 3 variant of uncertain significance. Immunohistochemistry for SDHA and SDHB showed absence of SDHB expression and allowed us to reclassify this variant as a class 4 “likely pathogenic” variant. At this stage, due to disease progression and genetic results, sunitinib was stopped and the patient started peptide receptor radionuclide therapy, which was not able to stop disease progression. In the end, the patient was treated with Averbuch chemotherapy (which is still ongoing), with an amelioration of clinical laboratory and imaging parameters.ConclusionClinical characteristics as well as data from SDHB immunohistochemistry well support reclassification of the novel germline SDHB c.314T>A gene variant as a class 4 “likely pathogenic” variant in the patient with metastatic PGL. This information might help clinicians in the management of its carriers and their families. In this case, only debulking surgery and chemotherapy with Averbuch scheme were clinically effective. Further studies are needed to better clarify and outline at which time point during the disease course SDHB patients should start Averbuch-scheme chemotherapy. |
| format | Article |
| id | doaj-art-8a1cb331999e4e269b6c836a563fb133 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-8a1cb331999e4e269b6c836a563fb1332025-08-20T03:42:02ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-03-011610.3389/fendo.2025.15774211577421A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature reviewStella Bernardi0Stella Bernardi1Stefania Zovato2Gianmaria Pennelli3Marco Cavallaro4Matteo Rovina5Chiara Dobrinja6Chiara Dobrinja7Alessandra Guglielmi8Fabrizio Zanconati9Fabrizio Zanconati10Daniela Mazzà11Alberto Nieri12Mirco Bartolomei13Francesca Schiavi14Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, ItalyEndocrinology Unit (UCO Medicina Clinica), ASUGI, Cattinara Teaching Hospital, Trieste, ItalyFamilial Cancer Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, ItalyDepartment of Medicine (DIMED) University of Padua, UOC Anatomia Patologica Azienda Ospedale-Università Padova, Padua, ItalyRadiology (UCO Radiologia), ASUGI, Maggiore Hospital, Trieste, ItalyEndocrinology Unit (UCO Medicina Clinica), ASUGI, Cattinara Teaching Hospital, Trieste, ItalyDepartment of Medical Surgical and Health Sciences, University of Trieste, Trieste, ItalySurgery (UCO Clinica Chirurgica), ASUGI, Cattinara Teaching Hospital, Trieste, ItalyOncology (SC Oncologia) ASUGI, Maggiore Hospital, ASUGI, Trieste, ItalyDepartment of Medical Surgical and Health Sciences, University of Trieste, Trieste, ItalyPathology (UCO Anatomia Patologica) ASUGI, Cattinara Teaching Hospital, Trieste, ItalyMedical Genetics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy0Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, Ferrara, Italy0Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, Ferrara, Italy1Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, ItalyIntroductionmost sympathetic paragangliomas are driven by germline pathogenic variants. Identifying germline succinate dehydrogenase B (SDHB) pathogenic variant has important management implications. Here we report a novel germline variant in the SDHB gene in a patient with metastatic paraganglioma and his response to available treatments.Case presentationa 37-year-old Serbian man was admitted to hospital due to hypertension, tachycardia and hyperhidrosis. Screening for secondary hypertension revealed elevated 24-h urinary normetanephrine. A CT scan showed the presence of a 54 x 76 mm retroperitoneal mass that surrounded the aorta, which was located below the pancreas and behind the duodenum. The patient was diagnosed having extra-adrenal sympathetic metastatic paraganglioma (PGL), for which we scheduled debulking surgery and genetic testing. Tumor debulking improved patient symptoms as well as signs of catecholamine excess and tumor mass effects. Meanwhile waiting for next-generation sequencing (NGS) results, the patient started a treatment with sunitinib. At this point, NGS results showed a novel and previously not reported germline SDHB c.314T>A gene variant, which was initially classified as a class 3 variant of uncertain significance. Immunohistochemistry for SDHA and SDHB showed absence of SDHB expression and allowed us to reclassify this variant as a class 4 “likely pathogenic” variant. At this stage, due to disease progression and genetic results, sunitinib was stopped and the patient started peptide receptor radionuclide therapy, which was not able to stop disease progression. In the end, the patient was treated with Averbuch chemotherapy (which is still ongoing), with an amelioration of clinical laboratory and imaging parameters.ConclusionClinical characteristics as well as data from SDHB immunohistochemistry well support reclassification of the novel germline SDHB c.314T>A gene variant as a class 4 “likely pathogenic” variant in the patient with metastatic PGL. This information might help clinicians in the management of its carriers and their families. In this case, only debulking surgery and chemotherapy with Averbuch scheme were clinically effective. Further studies are needed to better clarify and outline at which time point during the disease course SDHB patients should start Averbuch-scheme chemotherapy.https://www.frontiersin.org/articles/10.3389/fendo.2025.1577421/fullmetastatic paragangliomaSDHBPPGLAverbuch chemotherapyPRRTtyrosine kinase inhibitors |
| spellingShingle | Stella Bernardi Stella Bernardi Stefania Zovato Gianmaria Pennelli Marco Cavallaro Matteo Rovina Chiara Dobrinja Chiara Dobrinja Alessandra Guglielmi Fabrizio Zanconati Fabrizio Zanconati Daniela Mazzà Alberto Nieri Mirco Bartolomei Francesca Schiavi A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review Frontiers in Endocrinology metastatic paraganglioma SDHB PPGL Averbuch chemotherapy PRRT tyrosine kinase inhibitors |
| title | A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review |
| title_full | A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review |
| title_fullStr | A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review |
| title_full_unstemmed | A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review |
| title_short | A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review |
| title_sort | novel germline c 314t a sdhb variant in metastatic paraganglioma case report and literature review |
| topic | metastatic paraganglioma SDHB PPGL Averbuch chemotherapy PRRT tyrosine kinase inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1577421/full |
| work_keys_str_mv | AT stellabernardi anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT stellabernardi anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT stefaniazovato anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT gianmariapennelli anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT marcocavallaro anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT matteorovina anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT chiaradobrinja anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT chiaradobrinja anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT alessandraguglielmi anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT fabriziozanconati anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT fabriziozanconati anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT danielamazza anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT albertonieri anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT mircobartolomei anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT francescaschiavi anovelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT stellabernardi novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT stellabernardi novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT stefaniazovato novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT gianmariapennelli novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT marcocavallaro novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT matteorovina novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT chiaradobrinja novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT chiaradobrinja novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT alessandraguglielmi novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT fabriziozanconati novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT fabriziozanconati novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT danielamazza novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT albertonieri novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT mircobartolomei novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview AT francescaschiavi novelgermlinec314tasdhbvariantinmetastaticparagangliomacasereportandliteraturereview |